Escolar Documentos
Profissional Documentos
Cultura Documentos
As
recomendaes
da
Canadian
Task
Force
on
Preventive
Health
Care
O U.S. Preventive Service Task Force (USPSTF) dos EUA conclui, em sua reviso de 2007
das recomendaes de 2002 (http://www.ahrq.gov/clinic/uspstf/uspsprca.htm), no existir
evidncia suficiente para recomendar ou para no recomendar o exame rotineiro do
cncer de prstata com PSA e toque retal, uma vez que as evidncias de sua efetividade
so inexistentes, de baixa qualidade ou conflitantes e que o balano entre benefcios e
danos no pode ser determinado.
reviso
sistemtica
(http://www9.euskadi.net/sanidad/osteba/datos/d_99-
(http://www.hta.ac.uk/fullmono/mon102.pdf),
afirma
que
pouco
rastreamento (SELLEY, 1997). O NHS por meio do The Prostate Cancer Risk Management
Programme (Prostate Cancer Risk Management: UK Information Pack) recomenda a
estratgia de orientar todos os homens que solicitam a realizao da dosagem do PSA
sobre os riscos e benefcios da realizao do mesmo (NHS, 2002).
Cochrane
Collaboration,
em
reviso
sistemtica
realizada
em
2007,
(http://cochrane.bvsalud.org/cochrane/show.php?db=reviews&mfn=2635&id=&lang=pt&d
Concluso
Por no haver, at o momento, evidncias cientficas de que o rastreamento do cncer
de prstata possa produzir mais benefcio que dano, o Instituto Nacional de Cncer
recomenda que no se organizem aes de rastreamento para o cncer da prstata e
que homens que demandam espontaneamente a realizao de exames de rastreamento,
sejam informados por seus mdicos sobre os riscos e benefcios associados a esta
prtica.
O INCA continuar acompanhando o debate cientfico sobre este tema, podendo rever
sua posio quando estiverem disponveis os resultados dos estudos multicntricos em
curso.
Referncias Bibliogrficas
Andriole GL. Prostate Cancer Screening in the Prostate, Lung, Colorectal and
Ovarian (PLCO) Cancer Screening Trial: Findings From the Initial Screening Round
of a Randomized Trial. Journal of the National Cancer Institute, vol.97, No.6,
March 16, 2005.
Aus G. Prostate Cancer Screening Decreases the Absolute Risk of Being Diagnosed
with Advanced Prostate Cancer Results from a Prospective, Population-Based
Randomized Controlled Trial. European Urology 51:659-664.
DiSantostefano RL e Lavelle JP. The economic impact of prostate cancer
screening and treatment. North Caroline Medical Journal 2006; Volume 67,
Number 2: 158-160.
EURO OBSERVER, 2006. Euro Observer: The Health Bulletin of The European
Observatory on Health Systems and Policies. Autumn 2006, Volume 8. Number 3.
Feightner J.W. Screening for prostate cancer. In: Canadian Task Force on the
Periodic Health Examination. Canadian Guide to Clinical Preventive Health Care.
Ottawa: Health Canada, 1994; 812-23
Grover SA, Zowall H, Coupal L e Krahn MD. Prostate Cancer: 12. The economic
burden. Canadian Medical Association Journal 1999; 160 (5): 685-690.
Ilic, D, O'Connor, D., Green, S. e Wilt, T. Screening for prostate cancer
(Cochrane Review). In: The Cochrane Library, Issue 2, 2007. Oxford: Update
Software.
Postma R et al. Cancer Detection and Cancer Characteristics in the European
Randomized Study of Screening for Prostate Cancer (ERSPC) Section Rotterdam.
A Comparison of Two Rounds of Screening. European Urology 52: 89-97, 2007.
Schersten T, Baile MA, Asua J, Jonsson E. Prostate cancer screening. Evidence
synthesis and update. Statement of Finding. (INAHTA Joint Project). VictoriaGasteiz: Dpt. Of Health Basque Government. Basque Office for Health
Technology Assessment, Osteba. 1999
Schrder FH et al.Prostate Cancer Screening Decreases The Absolute Risk of
Being Diagnosed with Advancerd Prostate Cancer Results from a Prospective,
Population-Based Randomized Controlled Trial. European Urology 51:659-664,
2007.
Selley S, Donovan J, Faulkner A, Coast J, Gillatt D. Diagnosis, management and
screening of early localised prostate cancer. Health Technol Assess 1997;1 (2).
WHO. National cancer control programs:policies and managerial guidelines. 2nd
ed. 2002.